RecruitingNCT04425421

Recommendations for the Treatment of Children With Burkitt's Lymphoma

Sponsor

French Africa Pediatric Oncology Group

Enrollment

1,000 participants

Start Date

Nov 1, 2020

Study Type

OBSERVATIONAL

Conditions

Burkitt Lymphoma

Summary

This is the 4th LMB study by the French African Pediatric Oncology Group (GFAOP). The study hopes to be able to evaluate children earlier with stage I and II disease and to evaluate treatment response earlier so that the units can decide if a change in treatment is necessary, it is also hoped to provide an intensification of treatment for the stage IV disease.

Eligibility

Max Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study collects data on how children with Burkitt's lymphoma — a fast-growing type of B-cell lymphoma that can affect children's lymph nodes, abdomen, or other organs — are treated in real-world settings, to improve and standardize treatment guidelines. **You may be eligible if...** - Your child has a clinical diagnosis of Burkitt's lymphoma (confirmed by cytology or biopsy) - The lymphoma can be in any location in the body - Your child has not yet been treated for this lymphoma **You may NOT be eligible if...** - The tumor is not a B-cell lymphoma - Your child has already received treatment - Your child has another illness that makes the standard treatment incompatible - You as a parent refuse treatment Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.